



German Pharmacoepidemiological Research Database (GePaRD)

Pharmacoepidemiological research is predominantly conducted on the basis of large routine databases (secondary data). These databases facilitate the investigation of the utilization and safety of drugs, including vaccines, in real-world healthcare settings and the investigation of rare or delayed adverse events. In so-called PAS studies (Post-Approval Safety Studies), these databases are used to investigate the utilization and safety of newly approved drugs. They also provide important data for research on other healthcare services.

Since 2004, the Leibniz Institute for Prevention Research and Epidemiology – BIPS has been working on the establishment and maintenance of the project-based German Pharmacoepidemiological Research Database (short GePaRD). GePaRD is based on claims data from statutory health insurance (SHI) providers and currently includes information on about 25 million persons who have been insured with one of the participating providers since 2004 or later. Per data year, there is information on approximately 20% of the general population and all geographical regions of Germany are represented.

In addition to demographic data, GePaRD contains information on drug dispensations as well as outpatient (i.e., from general practitioners and specialists) and inpatient services and diagnoses. starting with the year 2004. New data are added on an annual basis. Before data are entered into the GePaRD database they are pseudonymized and validated through numerous plausibility checks. The entire process from data delivery to availability for studies can take up to two years, i.e., data from the year 2020 cannot be used before the end of 2022.

Data Subsets and Variables

GePaRD is linked via the central pharmaceutical number (PZN) to information from a central pharmaceutical reference database (CPR) established at BIPS. The structure of GePaRD and of the CPR is displayed in Table 1.

Table 1: Structure and content of GePaRD and of the CPR

GePaRD				CPR
Core data	Hospital data [§]	Outpatient data ^{\$\$}	Outpatient prescription data ^{\$\$\$}	Pharmaceutical information
<ul style="list-style-type: none"> - Entry/exit date - Sex - Year of birth - Marital status - Regional district - Nationality (German / not German) - Occupation - Insurance status (principal member/co-insured person) - Co-insured member (wife/child) - Family ID - Participation in disease management program - Reason for exit (e.g., death) 	<ul style="list-style-type: none"> - Hospital ID - Date of admission/discharge - Admission diagnosis/discharge diagnoses* (ICD-10) - OPS codes (surgery, diagnostic procedures, non-surgical therapeutic procedures#) - Birth weight (infants < 1 year) - Reason for discharge (e.g., death) 	<ul style="list-style-type: none"> - Physician ID - Physician specialty - Date of consultation - Diagnosis* (ICD-10) (on quarterly basis**) - Diagnostic certainty - Treatments## (claims code with date) 	<ul style="list-style-type: none"> - Physician/pharmacy ID - Date of prescription/dispensation - Central pharmaceutical number (PZN) - Dispensed quantity 	<ul style="list-style-type: none"> - Central pharmaceutical number (PZN) - Generic name - Brand - Manufacturer - Packaging size - Strength - Defined daily dose (DDD) - Pharmaceutical formulation - ATC GM code###

* Hospital and outpatient diagnoses are coded using the International Classification of Diseases, version 10 - German Modification (ICD-10-GM) with at least four digits

** Outpatient diagnoses refer to a period of three months, as physicians' services are settled quarterly

Diagnostic and surgical/medical procedures are coded using the Operations and Procedures Coding System (OPS)

Outpatient treatment / diagnostic procedures are coded using claim codes for outpatient services and procedures [Einheitlicher Bewertungsmaßstab, EBM]

Anatomical Therapeutic Chemical Classification System, German Modification

§ Provided to SHIs by hospitals

\$\$ Provided to SHIs by regional associations of statutory health insurance physicians [Kassenärztliche Vereinigungen]

\$\$\$ Provided to SHIs by pharmacies' electronic data processing centers [Apothekenrechenzentren]

Information on variables and their characteristics

There are only few variables with predefined values in GePaRD. The majority of variables can contain any codes that were billable to the health insurance provider in the respective period. The rare variables with fixed characteristics are described in the following.

Consequently, the issue of "missing values" (missings) only concerns these variables.

Master data:

- Sex (male, female, diverse, unknown, missing)
- Relation to primary insurance holder (spouse, own child, stepchild/foster child/grandchild, child without further specification, family member without further specification, other person, missing)
- Nationality (not German, German, unclear, missing)
- Reason for dropping insurance provider (death, change of provider, other reasons, missing)

Outpatient data:

- Diagnostic certainty (confirmed, exclusion, suspicion, condition after, missing).

Inpatient data:

- Type of hospitalization (inpatient, outpatient surgery, inpatient rehabilitation/additional treatment, inpatient preventive care, undefined, missing).

In addition, there may be missing values for the following variables:

- Hospital admission reason
- Hospital discharge reason
- Physician specialty group from lifelong physician number or facility number
- Occupation code of the primary insurance holder
- County of residence (5-digit municipality code)

Legal Restrictions

Access to the database is granted only to BIPS employees within the framework of officially approved research projects. It is only permitted to give third parties access to the data in cooperation with BIPS and after signing an agreement for visiting scientists. Project approval is based on the authorization by the SHI providers and the respective governing authorities (e.g., the Federal Office for Social Security for national SHI providers). For this purpose, BIPS applies for project-specific permits from the SHI providers. Upon approval, the SHI provider requests official project approval from the governing authority. This may be issued in accordance with Section 75 of the German Social Code (SGB) X if the interest warranting protection of the person concerned is not affected or if the public interest in the research or planning significantly outweighs the interest in personal privacy. The process of approval by the SHI providers and the respective governing authorities may take several months.

Information obligations

When asking for approval of a study, BIPS is required to send a short study outline (the so-called 'study proposal') to the SHIs and the governing authorities. The study proposal includes a short background, the research questions, the study methods, the variables, the data years, the scheduled operational time of the study, and the sponsor of the study. On request, the authorities may also receive a copy of the service agreement between BIPS and the sponsor of the study.

As a prerequisite to use the data from SHI providers for research purposes, BIPS is obliged to regularly inform the SHIs and the regulatory authorities about the progress of the study and to provide them with the final study report. Upon demand and after informing the sponsor of the study, SHI providers whose data are analyzed as well as the authorities may also receive the study protocol. Furthermore, BIPS has the obligation to regularly inform its Scientific Advisory Board about the progress of the study.

BIPS performs its studies according to applicable regulations and guidelines, such as the guidelines for Good Pharmacoepidemiology Practices (GPP) and for Good Epidemiological Practice (GEP). According to these guidelines and the standards of the Leibniz Association, BIPS is obliged to disseminate all results of its research in literature and at relevant scientific congresses.

Selected publications

- Amann U, Nadine W, Kollhorst B, Haug U. Prescribing of endothelin receptor antagonists and riociguat in women of childbearing age in a large German claims database study. *Reprod Toxicol* 2023; 119: 108415.
- Garcia Rodriguez LA, Ruigomez A, Schink T, Voss A, et al. Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries. *Expert Opin Drug Saf* 2023; 22: 493-500.
- Haug U, Kollhorst B, Schink T, Thöne K, et al. Investigating drug safety in pregnancy based on the German Pharmacoepidemiological Research Database (GePaRD): A proof-of-concept analysis on the association between valproate and spina bifida. *Pharmacoepidemiol Drug Saf* 2023; 32: 148-157.
- Heinig M, Schäfer W, Langner I, Zeeb H, et al. German mammography screening program: Adherence, characteristics of (non-)participants and utilization of non-screening mammography-a longitudinal analysis. *BMC Public Health* 2023; 23: 1678.
- Platzbecker K, Müller-Fielitz H, Foraita R, Koepp MJ, et al. In atrial fibrillation epilepsy risk differs between oral anticoagulants: active comparator, nested case-control study. *Europace* 2023; 25.
- Reinold J, Kollhorst B, Temme HL, Wentzell N, et al. Use of acitretin among girls and women of childbearing age and occurrence of acitretin-exposed pregnancies in Germany. *Clin Drug Investig* 2023; 43: 865-872.
- Riedel O, Braitmaier M, Dankhoff M, Hornschuch M, et al. Quality of life in bariatric patients up to twelve years after surgery - Results from a nationwide retrospective cohort study. *Obes Res Clin Pract* 2023; 17: 353-360.
- Riedel O, Braitmaier M, Langner I. Dementia in health claims data: The influence of different case definitions on incidence and prevalence estimates. *Int J Methods Psychiatr Res* 2023; 32: e1947.
- Riedel O, Viebrock J, Haug U. Overall survival in 92,991 colorectal cancer patients in Germany: Differences according to type of comorbidity. *Acta Oncol* 2023; 62: 1931-1938.
- Schwarz S, Hornschuch M, Pox C, Haug U. Polyp detection rate and cumulative incidence of post-colonoscopy colorectal cancer in Germany. *Int J Cancer* 2023; 152: 1547-1555.
- Tan EH, Robinson DE, Jödicke AM, Mosseveld M, et al. Drug utilization analysis of osteoporosis medications in seven European electronic health databases. *Osteoporos Int* 2023; 34: 1771-1781.
- Voss A, Kollhorst B, Platzbecker K, Amann U, et al. Risk profiles of new users of oral anticoagulants between 2011 and 2019 in Germany. *Clin Epidemiol* 2023; 15: 827-837.
- Voss A, Smits E, Swart KMA, Balabanova Y, et al. Time trends in patient characteristics of new rivaroxaban users with atrial fibrillation in Germany and the Netherlands. *Drugs Real World Outcomes* 2023; 10: 215-224.
- Wentzell N, Kollhorst B, Reinold J, Haug U. Use of methotrexate in girls and women of childbearing age, occurrence of methotrexate-exposed pregnancies and their outcomes in Germany: A claims data analysis. *Clin Drug Investig* 2023; 43: 109-117.
- Willame C, Dodd C, Durán CE, Elbers R, et al. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study. *Vaccine* 2023; 41: 251-262.

- Dengler R, Straub N, Froschauer S, Becker J, et al. Ambulante Spezialfachärztliche Versorgung (ASV): Eine multiperspektivische Studie zu Status quo, Herausforderungen und Perspektiven. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2022, in press.
- Asendorf M, Reinold J, Schink T, Kollhorst B, et al. Assessing the socioeconomic status in the German Pharmacoepidemiological Research Database (GePaRD): Description and exemplary application using the association with obesity. *GMS Medizinische Informatik, Biometrie und Epidemiologie* 2022; 18: Doc02.
- Braitmaier M, Kollhorst B, Heinig M, Langner I, et al. Effectiveness of mammography screening on breast cancer mortality - A study protocol for emulation of target trials using German health claims data. *Clin Epidemiol* 2022; 14: 1293-1303.
- Braitmaier M, Schwarz S, Kollhorst B, Senore C, et al. Screening colonoscopy similarly prevented distal and proximal colorectal cancer: a prospective study among 55–69-year-olds. *J Clin Epidemiol* 2022; 149: 118-126.
- Braitmaier M, Schwarz S, Kollhorst B, Senore C, et al. Screening colonoscopy similarly prevented distal and proximal colorectal cancer: A prospective study among 55–69-year-olds. *J Clin Epidemiol* 2022; 149: 118-126.
- Heinig M, Heinze F, Schwarz S, Haug U. Initial and ten-year treatment patterns among 11,000 breast cancer patients undergoing breast surgery—an analysis of German claims data. *BMC Cancer* 2022; 22: 130.
- Hornschuch M, Schwarz S, Haug U. 10-year prevalence of diagnostic and screening colonoscopy use in Germany: a claims data analysis. *Eur J Cancer Prev* 2022; 31: 497-504.
- Kollhorst B, Reinders T, Grill S, Eberle A, et al. Record linkage of claims and cancer registries data—Evaluation of a deterministic linkage approach based on indirect personal identifiers. *Pharmacoepidemiol Drug Saf* 2022; 31: 1287-1293.
- Pigeot I, Bongaerts B, Eberle A, Katalinic A, et al. Linkage of claims data with data from epidemiological cancer registries: Possibilities and limitations in the German federal states. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2022; 65: 615-623.
- Platzbecker K, Schäfer W, Haug U. Does the socioeconomic status differ between users of potentially NDMA-contaminated generic valsartan and users of brand-name valsartan in Germany? *GMS Medizinische Informatik, Biometrie und Epidemiologie* 2022; 18: Doc03.
- Platzbecker K, Voss A, Reinold J, Elbrecht A, et al. Validation of algorithms to identify acute myocardial infarction, stroke, and cardiovascular death in German health insurance data. *Clin Epidemiol* 2022; 14: 1351-1361.
- Platzbecker K, Wentzell N, Kollhorst B, Haug U. Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: Description of drug utilization and exposed pregnancies in Germany. *Mult Scler Relat Disord* 2022; 67: 104184.
- Reinold J, Braitmaier M, Riedel O, Haug U. Potential of health insurance claims data to predict fractures in older adults: A prospective cohort study. *Clin Epidemiol* 2022; 14: 1111-1122.
- Riedel O, Braitmaier M, Langner I. Stability of individual dementia diagnoses in routine care: Implications for epidemiological studies. *Pharmacoepidemiol Drug Saf* 2022; 31: 546-555.

- Rivero-Ferrer E, Olesen M, Plana E, Aguado J, et al. Characteristics of new users of acclidinium bromide, acclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. *Clin Drug Investig* 2022; 42: 319-331.
- Schäfer W, Reinders T, Schink T. Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions. *Vaccine* 2022; 40: 2168-2172.
- Schink T, Princk C, Braitmaier M, Haug U. Use of combined oral contraceptives and risk of venous thromboembolism in young women: A nested case-control analysis using German claims data. *BJOG: An International Journal of Obstetrics & Gynaecology* 2022; 129: 2107-2116.
- Scholle O, Asendorf M, Buck C, Grill S, et al. Regional variations in outpatient antibiotic prescribing in Germany: A small area analysis based on claims data. *Antibiotics* 2022; 11: 836.
- Schwarz S, Hornschuch M, Pox C, Haug U. Colorectal cancer after screening colonoscopy: 10-year incidence by site and detection rate at first repeat colonoscopy. *Clin Transl Gastroenterol* 2022; 14: e00535.
- Smits E, Andreotti F, Houben E, Crijns H, et al. Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. *Drugs Real World Outcomes* 2022; 9: 199-209.
- Thiyagarajan A, Platzbecker K, Ittermann T, Völzke H, et al. Estimating incidence and case fatality of thyroid storm in Germany between 2007 and 2017: A claims data analysis. *Thyroid* 2022; 32: 1307-1315.
- Wentzell N, Haug U. Characterization of pregnancies among women with epilepsy using valproate before or during pregnancy - A longitudinal claims data analysis from Germany. *Epilepsy Res* 2021; 179: 106838.
- Sturkenboom M, Schink T. *Databases for Pharmacoepidemiological Research*. Cham: Springer International Publishing; 2021.
- Schwarz S, Schäfer W, Horenkamp-Sonntag D, Liebentraut J, Haug U. Follow-up of 3 million persons undergoing colonoscopy in Germany: Utilization of repeat colonoscopies and polypectomies within 10 years. *Clinical and Translational Gastroenterology* 2021; 12(1): e00279.
- Schwarz S, Oppelt KA, Heinig M, Haug U. Potential of German claims data to characterize utilization of new cancer drugs: The example of crizotinib. *Future Oncology* 2021; 17(18): 2305-13.
- Scholle O, Neubert A, Riedel O, Toni I, Haug U. Repeated Use of Prescription Drugs in Pediatrics: Comprehensive Overview Based on German Claims Data. *Front Pharmacol* 2021; 12: 706682.
- Schäfer W, Wentzell N, Schink T, Haug U. Characterization of pregnancies exposed to St. John's wort and their outcomes: A claims data analysis. *Reprod Toxicol* 2021; 102: 90-7.
- Schäfer W, Reinders T, Riedel O, Haug U. How often are antidepressants prescribed off-label among older adults in Germany? A claims data analysis. *Br J Clin Pharmacol* 2021; 87(4): 1778-89.
- Riedel O, Klau S, Langner I, Bachmann C, Scholle O. Prevalence of multimodal treatment in children and adolescents with ADHD in Germany: a nationwide study based on health insurance data. *Child Adolesc Psychiatry Ment Health* 2021; 15(1): 76.

- Reinold J, Braitmaier M, Riedel O, Haug U. Anticholinergic burden: First comprehensive analysis using claims data shows large variation by age and sex. *PLoS One* 2021; 16(6): e0253336.
- Pigeot I, Tahden M, Zampatis D, Watson D, Forssen U, Kollhorst B. Worldwide availability of pharmacoepidemiological databases. 2021. In: *Databases for Pharmacoepidemiological Research* Cham: Springer International Publishing. 2021.
- Oppelt KA, Kuiper JG, Ingrassiotta Y, Ientile V, Herings RMC, Tari M, Trifirò G, Haug U. Characteristics and absolute survival of metastatic colorectal cancer patients treated with biologics: A real-world data analysis from three European countries. *Front Oncol* 2021; 11 (571).
- Heinig M, Schwarz S, Haug U. Self-selection for mammography screening according to use of hormone replacement therapy: A systematic literature review. *Cancer Epidemiol* 2021; Apr;71(Pt A):101812. doi: 10.1016/j.canep.2020.101812. Epub 2021 Feb 16.
- Haug U, Schink T. German Pharmacoepidemiological Research Database (GePaRD). 2021. In: *Databases for Pharmacoepidemiological Research*. Cham: Springer International Publishing. 2021.
- Fortuny J, von Gersdorff G, Lassalle R, Linder M, Overbeek J, Reinold J, Toft G, Timmer A, Dress J, Blin P, Droz-Perroteau C, Ehrenstein V, Franzoni C, Herings R, Kollhorst B, Moore N, Odsbu I, Perez-Gutthann S, Schink T, Rascher K, Rasouliyan L, Rothman KJ, Saigi-Morgui N, Schaller M, Smits E, Forstner M, Bénichou J, Bircher AJ, Garbe E, Rampton DS, Gutierrez L. Use of intravenous iron and risk of anaphylaxis: A multinational observational post-authorisation safety study in Europe. *Pharmacoepidemiol Drug Saf* 2021; 30(10): 1447-57.
- Enders D, Schink T, Stürmer T. Medicaid and Medicare. 2021. In: *Databases for Pharmacoepidemiological Research*. Cham: Springer International Publishing. 2021.
- Börnhorst C, Reinders T, Rathmann W, Bongaerts B, Haug U, Didelez V, Kollhorst B. Avoiding Time-Related Biases: A Feasibility Study on Antidiabetic Drugs and Pancreatic Cancer Applying the Parametric g-Formula to a Large German Healthcare Database. *Clin Epidemiol* 2021; 13: 1027-38.
- Vassilev ZP, Gabarró MS, Kaye JA, Saltus CW, Riedel O, Scholle O, Mehtälä J, Korhonen P, Garbe E, Zong J. Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: Results from observational studies in three countries. *Future Oncol* 2020; 16: 1889-901.
- Schink T, Wentzell N, Dathe K, Onken M, Haug U. Estimating the beginning of pregnancy in German claims data: Development of an algorithm with a focus on the expected delivery date. *Front Public Health* 2020; 8: 350.
- Reutfors J, Cesta CE, Cohen JM, Bateman BT, Brauer R, Einarisdóttir K, Engeland A, Furu K, Gissler M, Havard A, Hernandez-Diaz S, Huybrechts KF, Karlstad Ø, Leinonen MK, Li J, Man KKC, Pazzagli L, Schaffer A, Schink T, Wang Z, Yu Y, Zoega H, Bröms G. Antipsychotic drug use in pregnancy: A multinational study from ten countries. *Schizophr Res* 2020; 220: 106-15.
- Pisa FE, Reinold J, Kollhorst B, Haug U, Schink T. Individual antidepressants and the risk of fractures in older adults: A new user active comparator study. *Clin Epidemiol* 2020; 12: 667-78.
- Langner I, Riedel O, Czwikla J, Heinze F, Rothgang H, Zeeb H, Haug U. Linkage of routine data to other data sources in Germany: A practical example illustrating challenges and solutions. *Gesundheitswesen* 2020; 82(S 02): S117-s21.

- Kaguelidou F, Holstiege J, Schink T, Bezemer I, Poluzzi E, Mazzaglia G, Pedersen L, Sturkenboom M, Trifirò G. Use of antipsychotics in children and adolescents: A picture from the ARITMO population-based European cohort study. *Epidemiol Psychiatr Sci* 2020; 29: e117.
- Haug U. Verordnung von teratogenen Arzneimitteln bei Frauen im gebärfähigen Alter in Deutschland. *Bulletin zur Arzneimittelsicherheit* 2020; 4: 4-9.
- Scholle O, Kollhorst B, Haug U. Are prescribers not aware of cardiovascular contraindications for diclofenac? A claims data analysis. *J Intern Med* 2020; 287: 171-179.
- Kollhorst B, Jobski K, Krappweis J, Schink T, Garbe E, Schmedt N. Antidepressants and the risk of death in older patients with depression: A population-based cohort study. *PLoS One* 2019; 14: e0215289.
- Langner I, Haug U, Scholle O, Lindemann C, Schroder C, Riedel O. Potential Explanations for Increasing Methylphenidate Use in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Germany From 2004 to 2013. *J Clin Psychopharmacol* 2019; 39: 39-45.
- Langner I, Krieg V, Heidinger O, Hense HW, Zeeb H. Anreicherung eines GKV-Datensatzes mit amtlichen Todesursachen über einen Abgleich mit dem Epidemiologischen Krebsregister Nordrhein-Westfalen: Machbarkeitsstudie und Methodenvergleich. *Gesundheitswesen* 2019; 81: 629-635.
- Langner I, Ohlmeier C, Haug U, Hense HW, Czwikla J, Zeeb H. Implementation of an algorithm for the identification of breast cancer deaths in German health insurance claims data: a validation study based on a record linkage with administrative mortality data. *BMJ Open* 2019; 9: e026834.
- Langner I, Ohlmeier C, Zeeb H, Haug U, Riedel O. Individual mortality information in the German Pharmacoepidemiological Research Database (GePaRD): a validation study using a record linkage with a large cancer registry. *BMJ Open* 2019; 9: e028223.
- Oppelt KA, Luttmann S, Kraywinkel K, Haug U. Incidence of advanced colorectal cancer in Germany: Comparing claims data and cancer registry data. *BMC Med Res Methodol* 2019; 19: 142.
- Pisa FE, Reinold J, Kollhorst B, Haug U, Schink T. Antidepressants and the risk of traumatic brain injury in the elderly: Differences between individual agents. *Clin Epidemiol* 2019; 11: 185-196.
- Schäfer W, Princk C, Kollhorst B, Schink T. Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case-Control Study. *Drug Saf* 2019; 42: 1081-1089.
- Simbrich A, Thibaut J, Khil L, Berger K, Riedel O, Schmedt N. Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data. *Neuropsychiatr Dis Treat* 2019; 15: 1439-1457.
- Castellsague J, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Calingaert B, Bui C, Arana A, Laguna C, Gonzalez-Rubio F, Roso-Llorach A, Prados-Torres A, Perez-Gutthann S. Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. *Pharmacoepidemiol Drug Saf* 2018; 27: 953-961.
- Enders D, Kollhorst B, Engel S, Linder R, Pigeot I. Comparison of multiple imputation and two-phase logistic regression to analyse two-phase case-control studies with rich phase 1: a simulation study. *Journal of Statistical Computation and Simulation* 2018; 88: 2201-2214.

- Enders D, Ohlmeier C, Garbe E. The Potential of High-Dimensional Propensity Scores in Health Services Research: An Exemplary Study on the Quality of Care for Elective Percutaneous Coronary Interventions. *Health Serv Res* 2018; 53: 197-213.
- Masclee GMC, Straatman H, Arfè A, Castellsague J, Garbe E, Herings R, Kollhorst B, Lucchi S, Perez-Gutthann S, Romio S, Schade R, Schink T, Schuemie MJ, Scotti L, Varas-Lorenzo C, Valkhoff VE, Villa M, Sturkenboom M. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. *PLoS One* 2018; 13: e0204746.
- Oppelt KA, Haug U. Schmerztherapie bei Darmkrebspatienten. *Onkologe* 2018; 24: 848-860.
- Riedel O, Ohlmeier C, Enders D, Elsasser A, Vizcaya D, Michel A, Eberhard S, Schlothauer N, Berg J, Garbe E. The contribution of comorbidities to mortality in hospitalized patients with heart failure. *Clin Res Cardiol* 2018; 107: 487-497.
- Schink T, Kollhorst B, Varas Lorenzo C, Arfè A, Herings R, Lucchi S, Romio S, Schade R, Schuemie MJ, Straatman H, Valkhoff V, Villa M, Sturkenboom M, Garbe E. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. *PLoS One* 2018; 13: e0203362.
- Scholle O, Banaschewski T, Enders D, Garbe E, Riedel O. Use and Characteristics of Antipsychotic/Methylphenidate Combination Therapy in Children and Adolescents with a Diagnosis of Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol* 2018; 28: 415-422.
- Scholle O, Fegert JM, Kollhorst B, Öztürk EE, Riedel O, Kölch M. Predictors for Receiving Medication and/or Psychotherapy in Children Newly Diagnosed With ADHD: A Longitudinal Population-Based Cohort Study. *J Atten Disord* 2018; 24: 1087054718816172.
- Wentzell N, Haug U, Schink T, Engel S, Liebentraut J, Linder R, Onken M, Schaefer C, Dathe K. Prescribing valproate to girls and women of childbearing age in Germany: Analysis of trends based on claims data. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2018; 61: 1022-1029.
- Wentzell N, Schink T, Haug U, Ulrich S, Niemeyer M, Mikolajczyk R. Optimizing an algorithm for the identification and classification of pregnancy outcomes in German claims data. *Pharmacoepidemiol Drug Saf* 2018; 27: 1005-1010.
- Thöne K, Kollhorst B, Schink T. Non-Steroidal Anti-Inflammatory Drug Use and the Risk of Acute Myocardial Infarction in the General German Population: A Nested Case-Control Study. *Drugs Real World Outcomes*. 2017;4(3):127-37.
- Thöne K, Horn J, Mikolajczyk R. Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data. *BMC Infect Dis*. 2017;17(1):564.
- Schröder C, Enders D, Schink T, Riedel O. Incidence of herpes zoster amongst adults varies by severity of immunosuppression. *J Infect*. 2017;75(3):207-15.
- Schröder C, Dörks M, Kollhorst B, Blenk T, Dittmann RW, Garbe E, et al. Extent and risks of antidepressant off-label use in children and adolescents in Germany between 2004 and 2011. *Pharmacoepidemiol Drug Saf*. 2017;26(11):1395-402.
- Schröder C, Dörks M, Kollhorst B, Blenk T, Dittmann RW, Garbe E, et al. Extent and Risks of Antipsychotic Off-Label Use in Children and Adolescents in Germany Between 2004 and 2011. *J Child Adolesc Psychopharmacol*. 2017;27(9):806-13.

- Schmedt N, Khil L, Berger K, Riedel O. Incidence of Multiple Sclerosis in Germany: A Cohort Study Applying Different Case Definitions Based on Claims Data. *Neuroepidemiology*. 2017;49(3-4):91-8.
- Luque Ramos A, Ohlmeier C, Enders D, Linder R, Horenkamp-Sonntag D, Prochaska JH, et al. Initiation and duration of dual antiplatelet therapy after inpatient percutaneous coronary intervention with stent implantation in Germany: An electronic healthcare database cohort study. *Z Evid Fortbild Qual Gesundhwes*. 2017;120:31-8.
- Lindemann C, Langner I, Banaschewski T, Garbe E, Mikolajczyk RT. The Risk of Hospitalizations with Injury Diagnoses in a Matched Cohort of Children and Adolescents with and without Attention Deficit/Hyperactivity Disorder in Germany: A Database Study. *Front Pediatr*. 2017;5(220):220.
- La Gamba F, Corrao G, Romio S, Sturkenboom M, Trifirò G, Schink T, et al. Combining evidence from multiple electronic health care databases: performances of one-stage and two-stage meta-analysis in matched case-control studies. *Pharmacoepidemiol Drug Saf*. 2017;26(10):1213-9.
- Kollhorst B. Controlling for unobserved confounders in observational studies using large health care databases by means of instrumental variables in time-to-event analysis [dissertation]. Bremen: University of Bremen; 2017. Available from: <http://nbn-resolving.de/urn:nbn:de:gbv:46-00105848-17>.
- Jobski K, Schmedt N, Kollhorst B, Krappweis J, Schink T, Garbe E. Characteristics and drug use patterns of older antidepressant initiators in Germany. *Eur J Clin Pharmacol*. 2017;73(1):105-13.
- Jobski K, Kollhorst B, Garbe E, Schink T. The Risk of Ischemic Cardio- and Cerebrovascular Events Associated with Oxycodone-Naloxone and Other Extended-Release High-Potency Opioids: A Nested Case-Control Study. *Drug Saf*. 2017;40(6):505-15.
- Enders D. Designs and analytical strategies to control for unmeasured confounding in studies based on administrative health care databases [dissertation]. Bremen: University of Bremen; 2017. Available from: <http://nbn-resolving.de/urn:nbn:de:gbv:46-00105995-18>.
- Czwikla J, Jobski K, Schink T. The impact of the lookback period and definition of confirmatory events on the identification of incident cancer cases in administrative data. *BMC Med Res Methodol*. 2017;17(1):122.
- Castellsague J, Perez-Gutthann S, Calingaert B, Bui C, Varas-Lorenzo C, Arana A, et al. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. *Pharmacoepidemiol Drug Saf*. 2017;26(6):615-24.
- Schmedt N, Jobski K, Kollhorst B, Krappweis J, Ruther E, Schink T, et al. Treatment patterns and characteristics of older antipsychotic users in Germany. *Int Clin Psychopharmacol*. 2016;31(3):159-69.
- Schmedt N. Opportunities and Pitfalls in Drug Safety Studies after Marketing Approval An Evaluation with a Focus on Older Patients [dissertation]. Bremen: University of Bremen; 2016. Available from: <http://nbn-resolving.de/urn:nbn:de:gbv:46-00105399-11>.
- Riedel O, Bitters D, Amann U, Garbe E, Langner I. Estimating the prevalence of Parkinson's disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data. *Int J Geriatr Psychiatry*. 2016;31(8):938-43.
- Oteri A, Mazzaglia G, Pecchioli S, Molokhia M, Ulrichsen SP, Pedersen L, et al. Prescribing pattern of antipsychotic drugs during the years 1996-2010: a population-based database

- study in Europe with a focus on torsadogenic drugs. *Br J Clin Pharmacol*. 2016;82(2):487-97.
- Ohlmeier C, Langner I, Garbe E, Riedel O. Validating mortality in the German Pharmacoepidemiological Research Database (GePaRD) against a mortality registry. *Pharmacoepidemiol Drug Saf*. 2016;25(7):778-84.
- Ohlmeier C, Czwikla J, Enders D, Mikolajczyk R, Blindt R, Horenkamp-Sonntag D, et al. Percutaneous coronary interventions: Use between 2004 and 2012 in Germany. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2016;59(6):783-8.
- Jobski K. Methodological aspects of the implementation of drug safety and utilization studies based on claims data from statutory health insurance providers [dissertation]. Bremen: University of Bremen; 2016. Available from: <http://nbn-resolving.de/urn:nbn:de:gbv:46-00105231-10>.
- Ohlmeier C, Mikolajczyk R, Frick J, Prutz F, Haverkamp W, Garbe E. Incidence, prevalence and 1-year all-cause mortality of heart failure in Germany: a study based on electronic healthcare data of more than six million persons. *Clin Res Cardiol*. 2015;104(8):688-96.
- Ohlmeier C, Langner I, Hillebrand K, Schmedt N, Mikolajczyk R, Riedel O, et al. Mortality in the German Pharmacoepidemiological Research Database (GePaRD) compared to national data in Germany: results from a validation study. *BMC Public Health*. 2015;15:570.
- Ohlmeier C, Hoffmann F, Giersiepen K, Rothgang H, Mikolajczyk R, Appelrat HJ, et al. Linkage of statutory health insurance data with those of a hospital information system: feasible, but also "useful"? *Gesundheitswesen*. 2015;77(2):e8-e14.
- Ohlmeier C. Epidemiological healthcare analyses of cardiovascular diseases on the basis of routine data from statutory health insurance providers [dissertation]. Bremen: University of Bremen; 2015. Available from: <http://nbn-resolving.de/urn:nbn:de:gbv:46-00104704-12>.
- Mor A, Frøslev T, Thomsen RW, Oteri A, Rijnbeek P, Schink T, et al. Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project. *Infection*. 2015;43(4):453-72.
- Mikolajczyk R, Horn J, Schmedt N, Langner I, Lindemann C, Garbe E. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study. *JAMA Pediatr*. 2015;169(4):391-5.
- Kollhorst B, Behr S, Enders D, Dippel FW, Theobald K, Garbe E. Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study. *Diabetes Obes Metab*. 2015;17(12):1158-65.
- Jobski K, Kollhorst B, Schink T, Garbe E. The Risk of Opioid Intoxications or Related Events and the Effect of Alcohol-Related Disorders: A Retrospective Cohort Study in German Patients Treated with High-Potency Opioid Analgesics. *Drug Saf*. 2015;38(9):811-22.
- Holstiege J, Enders D, Schink T, Innocenti F, Oteri A, Bezemer I, et al. Trends in paediatric macrolide use in five European countries-a population-based study. *Eur J Clin Pharmacol*. 2015;71(8):991-9.
- Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005-2009. *J Infect*. 2015;70(2):178-86.
- Garbe E, Pigeot I. Benefits of large healthcare databases for drug risk research. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2015;58(8):829-37.
- Schink T, Holstiege J, Kowalzik F, Zepp F, Garbe E. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. *Vaccine*. 2014;32(6):645-50.

- Ohlmeier C, Linder R, Enders D, Mikolajczyk R, Haverkamp W, Horenkamp-Sonntag D, et al. Evaluating methods for intersectoral comparison of quality of care. A routine data analysis of elective percutaneous coronary interventions. *Methods Inf Med*. 2014;53(4):269-77.
- Ohlmeier C, Frick J, Prutz F, Lampert T, Ziese T, Mikolajczyk R, et al. Use of routine data from statutory health insurances for federal health monitoring purposes. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2014;57(4):464-72.
- Jobski K, Enders D, Amann U, Suzart K, Wallander MA, Schink T, et al. Use of rivaroxaban in Germany: a database drug utilization study of a drug started in hospital. *Eur J Clin Pharmacol*. 2014;70(8):975-81.
- Holstiege J, Schink T, Molokhia M, Mazzaglia G, Innocenti F, Oteri A, et al. Systemic antibiotic prescribing to paediatric outpatients in 5 European countries: a population-based cohort study. *BMC Pediatr*. 2014;14:174.
- Hense S, Schink T, Kreisel SH, Marcelon L, Simondon F, Tahden M, et al. Estimation of background incidence rates of Guillain-Barre syndrome in Germany - a retrospective cohort study with electronic healthcare data. *Neuroepidemiology*. 2014;43(3-4):244-52.
- Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E. HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data. *Hum Vaccin Immunother*. 2014;10(6):1729-33.
- Valkhoff VE, Schade R, t Jong GW, Romio S, Schuemie MJ, Arfè A, et al. Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: what size of data platforms and which study designs do we need to assess safety issues? *BMC Pediatr*. 2013;13:192.
- Schmedt N, Garbe E. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients with dementia. *J Clin Psychopharmacol*. 2013;33(6):753-8.
- Mikolajczyk RT, Kraut AA, Garbe E. Evaluation of pregnancy outcome records in the German Pharmacoepidemiological Research Database (GePaRD). *Pharmacoepidemiol Drug Saf*. 2013;22(8):873-80.
- Langner I, Garbe E, Banaschewski T, Mikolajczyk RT. Twin and sibling studies using health insurance data: the example of attention deficit/hyperactivity disorder (ADHD). *PLoS One*. 2013;8(4):e62177.
- Kraut AA, Langner I, Lindemann C, Banaschewski T, Petermann U, Petermann F, et al. Comorbidities in ADHD children treated with methylphenidate: a database study. *BMC Psychiatry*. 2013;13:11.
- Kraut AA. Clinical-epidemiological research based on data from statutory health insurance companies – potential and limitations [dissertation]. Bremen: University of Bremen; 2013. Available from: <http://nbn-resolving.de/urn:nbn:de:gbv:46-00103454-15>.
- Holstiege J, Garbe E. Systemic antibiotic use among children and adolescents in Germany: a population-based study. *Eur J Pediatr*. 2013;172(6):787-95.
- Garbe E, Kreisel SH, Behr S. Risk of subarachnoid hemorrhage and early case fatality associated with outpatient antithrombotic drug use. *Stroke*. 2013;44(9):2422-6.
- Garbe E, Kloss S, Suling M, Pigeot I, Schneeweiss S. High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications. *Eur J Clin Pharmacol*. 2013;69(3):549-57.

- Dörks M, Langner I, Dittmann U, Timmer A, Garbe E. Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study. *Eur Child Adolesc Psychiatry*. 2013;22(8):511-8.
- Dörks M, Langner I, Behr S, Timmer A, Garbe E. Database study of lenalidomide (Revlimid®) in Germany: monitoring off-label use. *GMS Medizinische Informatik, Biometrie und Epidemiologie*. 2013;9(3):Doc12.
- Dörks M. Routine data-based studies on off-label use in ambulatory care [dissertation]. Bremen: University of Bremen; 2013. Available from: <http://nbn-resolving.de/urn:nbn:de:gbv:46-00103457-18>.
- Behr S. Efficient use of phase 1 information in two-phase case-control studies based on administrative databases [dissertation]. Bremen: University of Bremen; 2013. Available from: <http://nbn-resolving.de/urn:nbn:de:gbv:46-00103296-17>.
- Suling M. Automated procedures in drug safety research [dissertation]. Bremen: University of Bremen; 2012. Available from: <http://nbn-resolving.de/urn:nbn:de:gbv:46-00102915-16>.
- Garbe E, Mikolajczyk RT, Banaschewski T, Petermann U, Petermann F, Kraut AA, et al. Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study. *J Child Adolesc Psychopharmacol*. 2012;22(6):452-8.
- Jobski K, Behr S, Garbe E. Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database. *Eur J Clin Pharmacol*. 2011;67(9):941-51.
- Garbe E, Suling M, Kloss S, Lindemann C, Schmid U. Linkage of mother-baby pairs in the German Pharmacoepidemiological Research Database. *Pharmacoepidemiol Drug Saf*. 2011;20(3):258-64.
- Pigeot I, Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. *Pharmacoepidemiol Drug Saf*. 2008;17(3):215-23.